Drivers of biodiagnostic development

David A. Giljohann and Chad A. Mirkin
Additional contact information
David A. Giljohann: Northwestern University
Chad A. Mirkin: Northwestern University

Nature, 2009, vol. 462, issue 7272, 461-464

Abstract: Abstract The promise of point-of-care medical diagnostics — tests that can be carried out at the site of patient care — is enormous, bringing the benefits of fast and reliable testing and allowing rapid decisions on the course of treatment to be made. To this end, much innovation is occurring in technologies for use in biodiagnostic tests. Assays based on nanomaterials, for example, are now beginning to make the transition from the laboratory to the clinic. But the potential for such assays to become part of routine medical testing depends on many scientific factors, including sensitivity, selectivity and versatility, as well as technological, financial and policy factors.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature08605 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:462:y:2009:i:7272:d:10.1038_nature08605

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature08605

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().